Anti-phospholipid antibodies: To anticoagulate or not to anticoagulate?

Rheumatology (United Kingdom)

Volumn 53, Issue 2, 2014, Pages 201-202

  Tincani, Angela ^a   Andreoli, Laura ^a   Shoenfeld, Yehuda ^b,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; VITAMIN D; WARFARIN;

AUTOIMMUNE DISEASE; BLOOD SAMPLING; EDITORIAL; HUMAN; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ASPIRIN; AUTOIMMUNE DISEASES; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; THROMBOSIS; WARFARIN;

EID: 84892526490     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket394     Document Type: Editorial

References (10)

1. Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 2013;12:752-7.
2. Alarcón-Segovia D, Boffa MC, Branch W et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003;12:499-503.
3. Cuadrado MJ, Bertolaccini ML, Seed PT et al. Low-dose aspirin versus low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial, in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology 2013;53:275-84.
4. Pengo V, Banzato A, Denas G et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013;12:832-4.
5. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20:206-18.
6. Pengo V, Ruffatti A, Legnani C et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714-8.
7. Ceccarelli F, Chighizola C, Finazzi G et al. Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and 'Cons'. Autoimmun Rev 2012;11:568-71.
8. Ruffatti A, Del Ross T, Ciprian M et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011;70:1083-6.
9. Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep 2011;13:59-69.
10. Agmon-Levin N, Blank M, Zandman-Goddard G et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011;70:145-50.